The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.
April 19th 2024
Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.
Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care
1.0 Credit / Hematology, Oncology
View More
Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
1.0 Credit / Hematology, Oncology
View More
Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
1.0 Credit / Hematology, Oncology
View More
Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
1.0 Credit / Hematology, Oncology
View More
Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure
1.0 Credit / Oncology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Advancing Myelofibrosis Treatment and Management With JAK Inhibitors and Specialty Pharmacist-led Strategies
1.5 Credits / Hematology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Exploring the Advancements in BTK Inhibitor Therapy for Mantle Cell Lymphoma and the Growing Impact of Oncology Pharmacists
1.0 Credit / Hematology, Oncology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Assessing Emerging Therapies and Multidisciplinary Practices in Managing Myelofibrosis
1.5 Credits / Hematology, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective Use
1.0 Credits / Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Management of DOAC-Associated Bleeding With Reversal Agents: A Comprehensive Approach for Health-System Pharmacists
1.0 Credit / Hematology
View More
Accelerated Approvals Withdrawn for Ibrutinib in Mantle Cell Lymphoma, Marginal Zone Lymphoma
April 7th 2023Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.
Read More
The Hematology/Oncology Pharmacy Association Makes Purposeful Strides Towards Inclusive Care
March 31st 2023The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.
Watch
Pharmacists Need to Be An Advocate, Recognized as Integral to Care Teams
March 29th 2023President (2022 to 2023) of the Hematology Oncology Pharmacists Association (HOPA) highlights the many ways that hematology/oncology pharmacists can collaborate with care teams to improve access to care at HOPA Annual Conference 2023 in Phoenix, Arizona from March 29 to April 1.
Watch
FDA Approves Rezafungin Injection for the Treatment of Candidemia, Invasive Candidiasis
March 24th 2023Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.
Read More
FDA Advisory Committee Supports Polatuzumab for Previously Untreated Diffuse Large B-cell Lymphoma
March 10th 2023On April 2, 2023, the FDA will announce the approval status of Roche’s supplemental Biologics License Application for polatuzumab in the treatment of diffuse large B-cell lymphoma.
Read More
Study Shows PCV13 Followed by PPSV23 Protects Against Pneumococcal Diseases in Patients With SCD
March 6th 2023The immunological efficacy of the 13-valent conjugate pneumococcal vaccine followed by 23-valent polysaccharide vaccine has been poorly documented in adult patients with sickle cell disease.
Read More
FDA Approves First-in-Class Factor VIII Therapy for Hemophilia A
February 24th 2023Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl; Sanofi] is high-sustained factor VIII replacement therapy indicated for routine prophylaxis and on-demand treatment to control bleeding episodes and for perioperative management in adults and children with hemophilia A.
Read More